



# MICRO-INDUCTIONS: WHAT ARE THEY

37



38


# Buprenorphine Microinduction In Opioid Dependent Persons



AllinaHealth

39

## ESSENTIALLY,



AllinaHealth

40

## EXAMPLE: MICRO-INDUCTION PROTOCOL

DAY	DOSE	FULL AGONISTS
1	Buprenorphine 150mcg buccal BID	Continue full dose
2	Buprenorphine 300mcg buccal BID	Continue full dose
3	Buprenorphine 600mcg buccal BID	Continue full dose
4	Buprenorphine/naloxone 2mg/0.5mg SL BID	Continue full dose
5	Buprenorphine/naloxone 4mg/1mg SL BID	Continue full dose
6	Buprenorphine/naloxone 8mg/2mg SL daily	Last day if no ongoing acute pain
7	Buprenorphine/naloxone 12mg/3mg SL daily	None if no ongoing acute pain
8+	Dosing can be adjusted based on patient's needs	

AllinaHealth

41

## EXAMPLE: RAPID MICRO-INDUCTION PROTOCOL

DAY	STEP 1	STEP 2	FULL AGONISTS
1	Buprenorphine 300mcg buccal Q3H x 2 doses	Buprenorphine 600mcg buccal Q3H x 6 doses	Continue full dose
2	Buprenorphine 600mcg buccal Q3H x 6 doses	Buprenorphine/naloxone 2mg/0.5mg SL Q3H x 2 doses	Continue full dose
3	Buprenorphine/naloxone 8mg/2mg SL Q3H x 2 doses		Last day if no ongoing acute pain
4+	Dosing can be adjusted based on patient's needs		



Sample protocols developed by Dr. Laura Fanucchi and the University of Kentucky Addiction Consult and Education Service and adapted from Weimer (2020) and Wong (2021).<sup>10,12</sup>

AllinaHealth


42

## CLINICAL COURSE

- AngioVac performed at 30+2 weeks.
  - 80% vegetations debulked.
- Clinical status improved and blood cultures negative 1-week post-procedure.
- Delivered via c-section at 32+5 weeks for fetal malpresentation & BPP of 4/8.



## TIMELINE OF EVENTS





# ANY QUESTIONS?

KATHERINE KATZUNG, MD, FACEP, FASAM

KATHERINE.KATZUNG@ALLINA.COM

AllinaHealth 

45



## References

Substance Abuse and Mental Health Services Administration. Clinical Guidance for Treating Pregnant and Parenting Women With Opioid Use Disorder and Their Infants. HHS Publication No. (SMA) 18-5054. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2018.

Kinsella M, Halliday LOE, Shaw M, Capel Y, Nelson SM, Kearns RJ. Buprenorphine Compared with Methadone in Pregnancy: A Systematic Review and Meta-Analysis. *Subst Use Misuse*. 2022;57(9):1400-1416. doi: 10.1080/10826084.2022.2083174. Epub 2022 Jun 25. PMID: 35758300.

Whiteman VE, Salemi JL, Mogos MF, Cain MA, Aliyu MH, Saliyu HM. Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, mortality, and the costs of medical care in the United States. *J Pregnancy*. 2014;2014:906723. doi: 10.1155/2014/906723. Epub 2014 Aug 28. PMID: 25254116; PMCID: PMC4164310.

Saia, K. A.; Potter, A. L.; LaBelle, C. T.; and Wason, K. F. Clinical Guidelines for the Treatment of Opioid Use Disorder in Pregnant and Parenting Patients. Unpublished treatment guidelines, Boston Medical Center, 2019.

Tolia VN, Patrick SW, Bennett MM, Murthy K, Sousa J, Smith PB, Clark RH, Spitzer AR. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. *N Engl J Med*. 2015 May 28;372(22):2118-26. doi: 10.1056/NEJMsa1500439. Epub 2015 Apr 26. PMID: 25913111.

MacMillan KDL. Neonatal Abstinence Syndrome: Review of Epidemiology, Care Models, and Current Understanding of Outcomes. *Clin Perinatol*. 2019 Dec;46(4):817-832. doi: 10.1016/j.clp.2019.08.012. Epub 2019 Aug 14. PMID: 31653310.

Haight SC, Ko JY, Tong VT, Bohm MK, Callaghan WM. Opioid Use Disorder Documented at Delivery Hospitalization - United States, 1999-2014. *MMWR Morb Mortal Wkly Rep*. 2018 Aug 10;67(31):845-849. doi: 10.15585/mmwr.mm6731a1. PMID: 30091969; PMCID: PMC6089335

AllinaHealth 

46

## References



Bell J, Towers CV, Hennessy MD, Heitzman C, Smith B, Chattin K. Detoxification from opiate drugs during pregnancy. *Am J Obstet Gynecol* 2016;215:374.e1-6 .

Substance Abuse and Mental Health Services Administration. A Collaborative Approach to the Treatment of Pregnant Women with Opioid Use Disorders. HHS Publication No. (SMA) 16-4978. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2016.

Jones HE, Johnson RE, Milio L. Post-cesarean pain management of patients maintained on methadone or buprenorphine. *Am J Addict* 2006;15:258-9.

Sachs HC. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Committee on Drugs. *Pediatrics* 2013;132:e796-809.

Terplan M, Hand DJ, Hutchinson M, Salisbury-Afshar E, Heil SH. Contraceptive use and method choice among women with opioid and other substance use disorders: A systematic review. *Prev Med* 2015;80:23-31.

Macintyre PE, Russell RA, Usher KA, Gaughwin M, Huxtable CA. Pain relief and opioid requirements in the first 24 hours after surgery in patients taking buprenorphine and methadone opioid substitution therapy. *Anaesth Intensive Care*. 2013 Mar;41(2):222-30. doi: 10.1177/0310057X1304100212. PMID: 23530789.

Choi S, Rosenbloom D, Stein MD, Raifman J, Clark JA. Differential Gateways, Facilitators, and Barriers to Substance Use Disorder Treatment for Pregnant Women and Mothers: A Scoping Systematic Review. *J Addict Med*. 2022 May-Jun 01;16(3):e185-e196. doi: 10.1097/ADM.0000000000000909. PMID: 34380985; PMCID: PMC8828806.

Boudova S, Casciani T, Weida J. Percutaneous debulking of tricuspid vegetations due to infectious endocarditis in pregnancy: a case report. *AJOG Glob Rep*. 2023 Apr 26;3(2):100204. doi: 10.1016/j.xagr.2023.100204. PMID: 37213793; PMCID: PMC10196985.

AllinaHealth 

47

## References



Dagher MM, Eichenberger EM, Addae-Konadu KL, Dotters-Katz SK, Kohler CL, Fowler VG, Federspiel JJ. Maternal and Fetal Outcomes Associated With Infective Endocarditis in Pregnancy. *Clin Infect Dis*. 2021 Nov 2;73(9):1571-1579. doi: 10.1093/cid/ciab533. PMID: 34111290; PMCID: PMC8563217.

De Aquino JP, Parida S, Sofuoglu M. The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder. *Clin Drug Investig*. 2021 May;41(5):425-436. doi: 10.1007/s40261-021-01032-7. Epub 2021 Apr 5. PMID: 33818748; PMCID: PMC8020374.

Wanar A, Saia K, Field TA. Delayed Norfentanyl Clearance During Pregnancy. *Obstet Gynecol*. 2020 Nov;136(5):905-907. doi: 10.1097/AOG.0000000000004106. PMID: 33030873.

Hagelberg NM, Fihlman M, Hemmilä T, Backman JT, Laitila J, Neuvonen PJ, Laine K, Olkkola KT, Saari TI. Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects. *Pharmacol Res Perspect*. 2016 Nov 3;4(6):e00271. doi: 10.1002/prp2.271. PMID: 28097004; PMCID: PMC5226287

AllinaHealth 

48